Literature DB >> 32807012

Pharmacotherapies and personalized medicine for alcohol use disorder: a review.

Falk W Lohoff1.   

Abstract

Alcohol use disorder (AUD) is highly prevalent and among the leading causes of morbidity and mortality in the United States. Pharmacotherapies for AUD are limited, thus making identification of patient subgroups that are most likely to respond favorably crucial. In this article, pharmacogenetic research on US FDA-approved and commonly prescribed off-label medications for the treatment of AUD is comprehensively reviewed. While the field has advanced in understanding pharmacotherapies for AUD and potential genetic moderators of treatment responses, the pharmacogenetic data to guide the prescribing clinician are limited and should be interpreted with caution. Precision medicine for AUD with more beneficial treatment responses and minimal side effects remains a high priority for further research.

Entities:  

Keywords:  alcohol dependence; alcohol use disorder; epigenetics; genetics; personalized medicine; pharmacotherapy; precision medicine; problematic drinking; psychiatric comorbidity; treatment response

Year:  2020        PMID: 32807012      PMCID: PMC7586357          DOI: 10.2217/pgs-2020-0079

Source DB:  PubMed          Journal:  Pharmacogenomics        ISSN: 1462-2416            Impact factor:   2.533


  192 in total

1.  PCSK9 is Increased in Cerebrospinal Fluid of Individuals With Alcohol Use Disorder.

Authors:  Ji Soo Lee; Daniel Rosoff; Audrey Luo; Martha Longley; Monte Phillips; Katrin Charlet; Christine Muench; Jeesun Jung; Falk W Lohoff
Journal:  Alcohol Clin Exp Res       Date:  2019-05-03       Impact factor: 3.455

Review 2.  The mechanisms of action of gabapentin and pregabalin.

Authors:  Graeme J Sills
Journal:  Curr Opin Pharmacol       Date:  2005-12-22       Impact factor: 5.547

Review 3.  Review: Pharmacogenetics of alcoholism treatment: Implications of ethnic diversity.

Authors:  Anita Cservenka; Megan M Yardley; Lara A Ray
Journal:  Am J Addict       Date:  2016-11-04

Review 4.  Treatment of restless legs syndrome: Evidence-based review and implications for clinical practice (Revised 2017)§.

Authors:  Juliane Winkelmann; Richard P Allen; Birgit Högl; Yuichi Inoue; Wolfgang Oertel; Aaro V Salminen; John W Winkelman; Claudia Trenkwalder; Cristina Sampaio
Journal:  Mov Disord       Date:  2018-05-14       Impact factor: 10.338

5.  Effect of oral acamprosate on abstinence in patients with alcohol dependence in a double-blind, placebo-controlled trial: the role of patient motivation.

Authors:  Barbara J Mason; Anita M Goodman; Sylvie Chabac; Philippe Lehert
Journal:  J Psychiatr Res       Date:  2006-03-20       Impact factor: 4.791

6.  A double-blind, placebo-controlled trial of topiramate for the treatment of comorbid cocaine and alcohol dependence.

Authors:  Kyle M Kampman; Helen M Pettinati; Kevin G Lynch; Kelly Spratt; Michael R Wierzbicki; Charles P O'Brien
Journal:  Drug Alcohol Depend       Date:  2013-06-28       Impact factor: 4.492

7.  Varenicline for treatment of alcohol dependence: a randomized, placebo-controlled trial.

Authors:  Andrea de Bejczy; Elin Löf; Lisa Walther; Joar Guterstam; Anders Hammarberg; Gulber Asanovska; Johan Franck; Anders Isaksson; Bo Söderpalm
Journal:  Alcohol Clin Exp Res       Date:  2015-09-28       Impact factor: 3.455

8.  Determination of genotype combinations that can predict the outcome of the treatment of alcohol dependence using the 5-HT(3) antagonist ondansetron.

Authors:  Bankole A Johnson; Chamindi Seneviratne; Xin-Qun Wang; Nassima Ait-Daoud; Ming D Li
Journal:  Am J Psychiatry       Date:  2013-09       Impact factor: 18.112

9.  Gabapentin reduces alcohol consumption and craving: a randomized, double-blind, placebo-controlled trial.

Authors:  Fernando A Furieri; Ester M Nakamura-Palacios
Journal:  J Clin Psychiatry       Date:  2007-11       Impact factor: 4.384

10.  OPRM1 Moderates Daily Associations of Naltrexone Adherence With Alcohol Consumption: Preliminary Evidence From a Mobile Health Trial.

Authors:  Christian S Hendershot; Sarah S Dermody; Jeffrey D Wardell; Michelle J Zaso; James L Kennedy; Susan A Stoner
Journal:  Alcohol Clin Exp Res       Date:  2020-02-26       Impact factor: 3.455

View more
  3 in total

1.  Alcohol use disorder is associated with DNA methylation-based shortening of telomere length and regulated by TESPA1: implications for aging.

Authors:  Jeesun Jung; Daniel L McCartney; Josephin Wagner; Daniel B Rosoff; Melanie Schwandt; Hui Sun; Corinde E Wiers; Luana Martins de Carvalho; Nora D Volkow; Rosie M Walker; Archie Campbell; David J Porteous; Andrew M McIntosh; Riccardo E Marioni; Steve Horvath; Kathryn L Evans; Falk W Lohoff
Journal:  Mol Psychiatry       Date:  2022-06-15       Impact factor: 15.992

Review 2.  Targeting Unmet Clinical Needs in the Treatment of Alcohol Use Disorder.

Authors:  Falk W Lohoff
Journal:  Front Psychiatry       Date:  2022-06-09       Impact factor: 5.435

3.  Burden of alcohol use disorders in China and the regions with different income levels over the world.

Authors:  Xiang Qu; Mi Liu; Changrong Ke; Juanjuan Liang; Yuanze Du; Liqun Yao; Juanjuan Li; Guixian Mu; Shiwei Liu; Chunping Wang
Journal:  J Glob Health       Date:  2021-12-30       Impact factor: 4.413

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.